Back to overview

Primary results from the SAUL study

Prof. Jens Bedke (DE) and Prof. Maria José Ribal discussed the primary results from the SAUL study with Prof. Axel Merseburger (DE). SAUL is a prospective multinational single-arm study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract.

Read the written report about the study here.